FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
AbbVie follows Gilead in throwing Xilio a lifeline.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.